Results 51 to 60 of about 4,821 (183)

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle [PDF]

open access: yes, 2015
Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance.
Alloosh, Mouhamad   +7 more
core   +1 more source

The dual amylin‐ and calcitonin‐receptor agonist KBP‐042 increases insulin sensitivity and induces weight loss in rats with obesity [PDF]

open access: yesObesity, 2016
ObjectiveIn this study, KBP‐042, a dual amylin‐ and calcitonin‐receptor agonist, was investigated as a treatment of obesity and insulin resistance in five different doses (0.625 µg/kg–10 µg/kg) compared with saline‐treated and pair‐fed controls.MethodsRats with obesity received daily s.c.
Hjuler, Sara Toftegaard   +6 more
openaire   +3 more sources

Amylin in the periphery II: An updated mini-review [PDF]

open access: yes, 2006
Amylin is a polypeptide that is cosecreted with insulin from the beta cells of the pancreas. Therefore, in states of diabetes in which the beta-cell mass is largely depleted or dysfunctional, insulin and amylin secretion are also lost or dysregulated ...
Andrikopoulos, S   +2 more
core   +1 more source

Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists : a real-world study in 66 583 patients [PDF]

open access: yes, 2017
Background Real world outcomes of addition or switch to insulin therapy in type 2 diabetes (T2DM) patients on glucagon-like paptide-1 receptor agonist (GLP-1RA) with inadequately controlled hyperglycaemia, are not known.
American Diabetes Association   +25 more
core   +1 more source

Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1/2 dorsal root ganglia

open access: yesThe Journal of Headache and Pain
Background The upper cervical dorsal root ganglia (DRG) are important for the transmission of sensory information associated with the back of the head and neck, contributing to head pain.
Tayla A. Rees   +5 more
doaj   +1 more source

What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters [PDF]

open access: yes, 2016
Diabetes Mellitus (DM) is a syndrome caused by various etiologies. The clinical manifestations of DM are not indicative of the cause of the disease, but might be indicative of the stage and severity of the disease process.
Abdul-Rasoul   +110 more
core   +3 more sources

Effects of a selective long‐acting amylin receptor agonist on alcohol consumption, food intake and body weight in male and female rats [PDF]

open access: yesAddiction Biology, 2020
AbstractAlcohol use disorder is a complex neuropsychiatric disorder affecting both males and females worldwide; however, the efficacy of current pharmacotherapies varies. Recent advances show that gut‐brain peptides, like amylin, regulate alcohol behavioural responses by acting on brain areas involved in alcohol reward processes.
Aimilia Lydia Kalafateli   +4 more
openaire   +2 more sources

Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects

open access: yesPharmacology Research & Perspectives
Obesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti‐obesity pharmaceuticals has already demonstrated significant efficacy.
Igor Rubinić   +2 more
doaj   +1 more source

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

open access: yesJournal of Pharmacy & Pharmaceutical Sciences
Excess adiposity can contribute to metabolic complications, such as type 2 diabetes mellitus (T2DM), which poses a significant global health burden.
Arianne Morissette   +2 more
doaj   +1 more source

Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.

open access: yesPLoS ONE, 2013
Combination therapy is being increasingly used as a treatment paradigm for metabolic diseases such as diabetes and obesity. In the peptide therapeutics realm, recent work has highlighted the therapeutic potential of chimeric peptides that act on two ...
James L Trevaskis   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy